Resistin is known as an adipocyte-specific secretory hormone that can cause insulin resistance and decrease adipocyte differentiation. It can be regulated by sexual hormones, but the mechanism of estrogen's actions is still not clear. Using 3T3-L1 adipocytes, we found that 17␤-estradiol (E 2 ) up-regulated resistin mRNA expression in a dose-and time-dependent manner. The concentration of E 2 that increased resistin mRNA levels by 100 -250% was approximately 1 nM for a range of 1-24 h of treatment. Treatment with either actinomycin D or cycloheximide prevented E 2 -stimulated resistin mRNA expression, suggesting that the effect of E 2 requires new mRNA and protein synthesis. Although E 2 was shown to increase activities of the estrogen receptor (ER) and MAPK kinase 1 and the association of nuclear ER␣ and CCAAT/enhancer binding protein-␣ with the resistin gene promoter, signaling was demonstrated to be blocked by pretreatment with either ICI182780 or PD98059. Neither SB203580 nor LY294002 changed the E 2 -increased levels of resistin mRNA, but they respectively inhibited E 2 -stimulated phosphorylation of p38 MAPK and Akt. These results imply the ER␣, ERK, and CCAAT/enhancer binding protein-␣ are necessary for the E 2 stimulation of transcription from the resistin promoter. Moreover, PD98059, but not SB203580 or LY294002, antagonized E 2 -increased resistin protein release. These data suggest that E 2 likely modifies the distribution of the resistin protein between the intracellular and extracellular compartments via an ERK-dependent pathway. (Endocrinology 147: 4496 -4504, 2006) 
R
ESISTIN IS A cysteine-rich hormone that was first isolated from adipose tissues and found to link obesity to type II diabetes in rodents (1) . In particular, administration of exogenous resistin into normal mice causes glucose intolerance and hyperinsulinemia, whereas an antiresistin antibody decreases blood glucose and improves insulin sensitivity in obese mice (1) . In addition, resistin suppresses insulin-stimulated glucose uptake in adipocytes (1) and muscle cells (2) . Moreover, transgenic mice overexpressing a dominant-negative form of resistin showed increased adipogenesis and improved insulin sensitivity (3) . However, the involvement of resistin in obesity and insulin resistance in humans is still controversial. Some studies have shown no relationship of resistin gene expression with body weight or insulin resistance (4) . Others found that resistin mRNA expression in adipose tissues of obese humans is higher than that in normal subjects (5) , that a single-nucleotide polymorphism in the resistin gene promoter was associated with obesity (6) and diabetes (7) , and that the plasma resistin levels were elevated in patients with obesity (8) and type II diabetes (9) . One possible explanation for these disparate findings is the presence of the various isoforms (10, 11) or dimers (12) of resistin. This contention may also explain the functional diversity of resistin in different species or systems. For example, resistin regulates fasted blood glucose levels, lipid metabolism, catecholamine release, inflammation, hepatic insulin resistance, and proliferation and activation of endothelial cells and smooth muscle cells (4, (13) (14) (15) (16) . The mechanisms of actions of resistin can stimulate muscle cell proliferation through activation of ERK1/2 and phosphatidylinositol 3-kinase (PI3K) (16) as well as inhibit insulin signaling of 3T3-L1 adipocytes through the induction of the gene expression of suppressor of cytokine signaling 3 (17) .
Despite the importance of resistin, relatively little is known about the control of production of resistin by sexual hormones (18) . Although sexual differences of resistin levels were found in mice (male Ͻ female) (19) , rats (male Ͼ female) (20) , and humans (male Ͻ female) (21) , suggesting the possible involvement of sex steroids in regulating resistin production, the results did not demonstrate a direct effect of estrogens on resistin gene expression or protein secretion by adipocytes. In a murine study, an ovariectomy increased resistin mRNA abundance of adipose tissues without changing plasma resistin levels, whereas estrogen replacement reduced resistin mRNA (19) . In contrast, an ovariectomy did not change any level of resistin mRNA of rats (20) . Whether estrogens affect resistin gene expression and protein secretion is still controversial based on those studies. The fact that the signal element responsible for transducing the action of estrogens on resistin gene expression and secretion has not been identified has caused much controversy surrounding the possible role of estrogens in regulating resistin expression. Additional in vitro cell lines that are free from interfering influences present in whole animals and that allow precise estrogen concentrations to be achieved should be excellent systems for studying the signal element(s) through which estrogens regulate resistin level.
In this study, we used 3T3-L1 adipocytes to examine the influence and the signaling of 17␤-estradiol (E 2 ) on resistin gene expression and protein secretion. We investigated whether E 2 -regulated resistin gene expression and protein secretion are dependent on the CCAAT/enhancer binding protein (C/EBP), MAPK, and/or PI3K pathways. C/EBP␣, MAPK, and PI3K were chosen because they have been reported to be essential signal transducers of E 2 in the regulation of other genes in 3T3-L1 adipocytes (22, 23) , and because C/EBP␣ has been reported to stimulate resistin expression (24 -26) .
Materials and Methods

Chemical reagents
All materials (e.g. E 2 , estriol, estrone, and so forth) were purchased from Sigma Chemical Co. (St. Louis, MO) unless otherwise stated. DMEM, penicillin-streptomycin, fetal bovine serum (FBS), trypsin, agarose, the 1-kb plus DNA ladder marker, and the protein marker were purchased from GibcoBRL (New York, NY). Except for the resistin antibody, which was obtained from Linco Research (St. Charles, MO), all other antibodies [phospho-ERKs, ERK1, ERK2, estrogen receptor (ER), C/EBP␣, goat anti-guinea pig IgG-horseradish peroxidase, etc.) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The 3Ј-RACE system, Trizol, and Taq polymerase were purchased from Invitrogen Life Science Technologies (Carlsbad, CA).
Cell culture
3T3-L1 adipocytes (American Type Culture Collection, Manassas, VA) were obtained according to a published method (27) , in which 2-d postconfluent 3T3-L1 preadipocytes (3 ϫ 10 6 cells in a 10-cm plate) were treated with DMEM containing a final concentration of 10 m dexamethasone, 0.5 mm 3-isobutyl-1-methylxanthine, and 10% FBS for 48 h. The medium was then changed to DMEM containing 10% FBS for an additional 6 -10 d. With this protocol, greater than 90% adipocyte differentiation was achieved, as indicated by phenotypical appearance and triglyceride accumulation (27) . Differentiated adipocytes expressed 3.4-fold more resistin mRNA than did preadipocytes or differentiating preadipocytes.
For all experiments, adipocytes were serum-starved for 12 h in DMEM containing 0.1% (fatty acid free) BSA and then, unless noted otherwise, incubated with or without hormones at various concentrations for the indicated time periods. Estrogens (E 2 , estriol, and estrone), dexamethasone, diethylstilbestrol, and genistein were dissolved in 0.1% ethanol and sterile medium for cell treatment. Actinomycin D (Acti-D; 5 g/ml), cycloheximide (5 g/ml), PD98059 [a MAPK kinase 1 (MEK1) inhibitor (28) (27, 32) . In the experiments, serum-starved 3T3-L1 adipocytes were pretreated with or without either Acti-D for 30 min or other inhibitors for 90 min. Then, adipocytes were stimulated with or without E 2 (1 nm) for the indicated time period. After treatment, resistin mRNA and protein levels were measured. Despite the high dose of some inhibitors used in the study, no adverse effects on cell viability of adipocytes for 24 h were noted (27) .
ELISA for resistin mRNA and extracellular resistin protein
Resistin mRNA levels were measured using a commercial PCR ELISA kit with digoxigenin labeling and detection (Roche Applied Science, Mannheim, Germany) (27) . The forward and reverse primers were 5Ј-GTACCCACGGGATGAAGAACC-3Ј and 5Ј-GCAGAGCCACAGGAG-CAG-3Ј for mouse resistin (accession no. AF323080) and 5Ј-CCAGGGT-GTGATGGTGGGAATG-3Ј and 5Ј-CGCACGATTTCCCTCTCAGCT-G-3Ј for actin (accession no. X03672), respectively. Sample resistin mRNA levels were determined by relation to a standard curve of resistin cDNAs, ranging from 3-200 ng/well (OD 405nm ϭ 0.1141 ϩ 0.0031 ϫ ng DNA/well; r 2 ϭ 0.998). An almost-linear range in the number of PCR amplifications for resistin was observed between 20 and 40 cycles when compared with the ␤-actin standard. Thus, 30 cycles of PCR amplification were subsequently used for all experiments. After normalization to ␤-actin mRNA, resistin levels were expressed as a percentage of the control. To analyze the secreted resistin protein, a homologous ELISA procedure (27) was used. The interassay and intraassay coefficients of variation in the ELISA were 7-9 and 3-4%, respectively. The reproducible results were obtained in the range of resistin of from 5-80 ng per well (OD 405nm ϭ 0.1269 ϩ 0.0044 ϫ ng/well; r 2 ϭ 0.979).
Immunoprecipitation and Western blot analysis
ER␣ and C/EBP␣ were immunoprecipitated according to the method described by Chen et al. (27) . After experimental treatment, adipocytes were washed twice in PBS and then lysed in 1 ml buffer containing 20 mm Tris-HCl (pH 7.6), 1 mm EDTA, 1 mm Na 3 VO 4 , 0.2% Triton X-100, and 1 mm phenylmethylsulfonyl fluoride. Lysate was agitated for 15 min at 4 C and then centrifuged for 10 min to collect the supernatant. Nuclear protein was gained by swelling cells on ice for 10 min in a buffer containing 10 mm Tris-HCl (pH 7.4), 10 mm NaCl, 3 mm MgCl 2 , and 0.5% Nonidet P-40. The nuclear lysate was centrifuged at 500 ϫ g, and the nuclear pellet was resuspended in lysis buffer. The protein content of the lysates was determined in duplicate by the dye-binding method (33) using a Bio-Rad (Richmond, CA) microplate reader and BSA (Sigma) as a standard. An aliquot of the supernatant (1 mg protein) was preincubated for 1 h at 4 C with either rabbit polyclonal ER␣ or C/EBP␣ antibody or with preimmunized normal rabbit serum (NRS) as the control. The mixture was incubated with 20 l protein A-agarose (Santa Cruz Biotechnology) overnight at 4 C. Total amounts of ER␣ and C/EBP␣ in the immunoprecipitates were measured by Western blot analysis with ER␣ and C/EBP␣ antibodies, respectively. The amounts of phospho-ERK1/2 proteins indicative of ER␣ activation (22) in the immunoprecipitates were measured by Western blot analysis using a phospho-ERK1/2 antibody. The Western blot method for analyzing phospho-ERK1/2 and other proteins was performed on supernatant fractions of adipocytes (50 g of protein) that were separated by 12.5% SDS-PAGE with a loading buffer [100 mm Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 0.2% bromophenol blue, and 10% ␤-mercaptoethanol) and then blotted onto a membrane (27) . The immunoblots were analyzed with the primary (ϳ0.2 g/ml) and secondary (ϳ0.2 g/ml) antibodies. After normalization to ␤-actin protein, levels of the intracellular resistin protein and kinases were expressed as a percentage of the control, unless noted otherwise.
Chromatin immunoprecipitation (ChIP) assays
The ChIP method was adapted from Hartman et al. (24) to analyze the association of ER␣ and C/EBP␣ with the resistin gene promoter. After adipocytes were pretreated with either ICI182780 or PD98059 for 90 min and then stimulated with or without 1 nM E 2 for the indicated time periods, they were collected by washing twice with PBS and crosslinking with 1% formaldehyde in PBS at 37 C for 10 min. Cells were then rinsed twice with ice-cold PBS, centrifuged for 4 min at 700 ϫ g, and resuspended in lysis buffer [50 mm Tris-HCl (pH 8.1), 1% SDS, and 5 mm EDTA). After a 20-min incubation on ice, samples were sonicated with 15-sec pulses three times on ice. The lysates were centrifuged at 14,000 ϫ g for 10 min, and then the collected supernatant was diluted in buffer I (1% Triton X-100, 2 mm EDTA, 150 mm NaCl, 20 mm Tris-HCl, pH 8.1) with protease inhibitors (Roche Molecular Biochemicals). Samples were precleared with 2 g sheared salmon sperm DNA and 45 l protein A-agarose beads (Santa Cruz Biotechnology) for 2 h. They were then immunoprecipitated with either C/EBP␣ or ER␣ antibodies or with NRS. After incubation overnight, samples were then incubated with 45 l protein A-agarose beads for 1 h followed by 10-min sequential washes in buffer II (20 mm Tris-HCl, 0.1% SDS, 1% Triton X-100, 2 mm EDTA, 150 mm NaCl), buffer III (20 mm Tris-HCl, 0.1% SDS, 1% Triton X-100, 2 mm EDTA, 500 mm NaCl), buffer IV (10 mm Tris-HCl, 0.25% m LiCl, 1% Nonidet P-40, 1% deoxycholate, 1 mm EDTA), and Tris-EDTA buffer. Precipitates were then extracted by incubating with elution buffer (1% SDS, 0.1 m NaHCO 3 ) at 65 C for 6 h or overnight. DNA fragments were purified using a Geneaid PCR purification kit. An aliquot of 2-10 l of purified sample was used in the 30 cycles of PCR. According to the method by Hartman et al. (24) , primers surrounding the resistin transcription start site had sequences of 5Ј-GTCTTGGCTCCTAGCCT-TGC-3Ј and 5Ј-GTTGACTTCTGGCCCATCC-3Ј.
Statistical analysis
Data are expressed as the mean Ϯ se. Unpaired Student's t test was used to examine differences between the control and E 2 -treated groups. One-way ANOVA followed by the Student-Newman-Keuls multiplerange test were used to examine differences among multiple groups. Differences were considered significant at P Ͻ 0.05. Statistics were performed using SigmaStat (Jandel Scientific, Palo Alto, CA) and data that were transformed with the logarithm.
Results
Effects of E 2 on resistin mRNA expression
E 2 increased the steady-state levels of resistin mRNA in a concentration-dependent ( Fig. 1A ) and time-dependent ( Fig.   1B ) manner. The activation concentration of E 2 to increase 100 -250% of resistin mRNA levels was approximately 1 nm after 1-24 h of treatment. The possibility that the E 2 -induced stimulation in resistin mRNA expression resulted from the alteration in resistin mRNA stability was also examined (Fig.  1C ). 3T3-L1 adipocytes were pretreated with the transcriptional inhibitor Acti-D and then treated with or without 1 nm E 2 . E 2 did not alter the basal half-life of resistin mRNA induced by Acti-D alone (Fig. 1C) . However, treatment with Acti-D prevented E 2 -stimulated resistin mRNA expression (Fig. 1, B and C).
Effects of E 2 on resistin protein expression, stability, and secretion
To determine whether E 2 -stimulated resistin gene expression also occurred at the level of translation, changes in the intracellular resistin protein content as well as the release of resistin into culture medium were measured (Fig. 2) . Intracellular levels of resistin protein significantly increased in the presence of 1 nm E 2 after 24 h, but not 1-12 h, of treatment ( Fig. 2A) . However, E 2 induced resistin protein release after 1-24 h of treatment (Fig. 2B ).
Effect of cycloheximide on E 2 -induced increases in resistin protein and mRNA expression
The possibility that E 2 -stimulated release of resistin protein was related to changes in resistin protein stability was also examined (Fig. 2, C and D) . 3T3-L1 adipocytes were pretreated with the translational inhibitor cycloheximide and then treated with or without 1 nm E 2 . Because cycloheximide was previously demonstrated to reduce the 50% amounts of FIG. 1. The stimulatory effect of E 2 on resistin mRNA expression in 3T3-L1 adipocytes did not result from an alteration in resistin mRNA stability. A, Dose-dependent effect of E 2 was observed 6 h after treatment; B, time-dependent effect of E 2 (1 nM) was observed; C, E 2 did not alter resistin mRNA stability induced by Acti-D (5 g/ml) alone. Data are expressed as the means Ϯ SE from replicates of three experiments after the quantitative digoxigenin-PCR ELISA. SE bars are too small to be seen in B and C. In A, the control experiment was that not treated with E 2 , whereas in B and C, controls were set at time 0 when E 2 was added in the beginning. a-d, Groups with different letters (A and B) are significantly different (P Ͻ 0.05) from each other. *, P Ͻ 0.05 vs. control (C).
FIG. 2. E 2 (1 nM) increased the intracellular (A) and extracellular (B)
resistin protein levels in 3T3-L1 adipocytes with time-dependent differences. Also, E 2 tended to affect resistin protein stability induced by cycloheximide (CHX; 5 g/ml) alone (C and D). Data are expressed as the means Ϯ SE from replicates of three experiments. SE bars are too small to be seen in A-D. In A, B, and D, the control was represented without E 2 treatment, whereas in C, it was set at time 0 when E 2 was added in the beginning. *, P Ͻ 0.05 vs. control (A-C), CHX vs. CHXϩE 2 at a given time (D).
the intracellular resistin protein during 20 -45 h of treatment (26) , the duration of the exposure of E 2 was extended to 45 h. E 2 had no significant effect on protein stability based on the observations of no significant changes in the intracellular resistin protein content (Fig. 2C) . However, E 2 tended to increase the amounts of resistin protein released into the extracellular medium when compared with two cycloheximide treatment groups in the presence and absence of E 2 (Fig.  2D ). In addition, treatment with cycloheximide prevented E 2 -stimulated resistin protein expression (Fig. 2, A and C) .
To further examine whether E 2 -stimulated expression of the adipocyte resistin gene is mediated via other proteins, adipocytes were pretreated with or without cycloheximide for 90 min and then stimulated with or without 1 nm E 2 for 1 h (Table 1 ), 6 h (data not shown), and 24 h (data not shown). Treatment with cycloheximide alone did not alter resistin mRNA expression of adipocytes when compared with the control. Cycloheximide, however, prevented E 2 -induced increases in resistin gene expression during the 24-h treatment.
Effect of E 2 on ER
To further demonstrate whether E 2 -induced expression of the resistin gene is mediated through ER, adipocytes were pretreated with the ER antagonist ICI182780 (1 m) for 90 min, and then they were incubated with or without 1 nm E 2 for 1 h (Table 1) . Treatment with ICI182780 alone did not alter the steady-state level of resistin mRNA but prevented E 2 -induced increases in resistin mRNA expression. Because the rapid effects of estrogens on white adipocytes have been described at the plasma membrane level including activation of ERK MAPK activity and because ERK MAPK has been implicated as being necessary for the E 2 stimulation of adipocyte proliferation from the ER (22), the effect of E 2 on ER activity was assessed by changes in the amount of the phosphorylated form of ERK MAPK. Indeed, treatment with ICI182780 prevented E 2 -induced increases in the amount of phospho-ERK1/2 proteins (Table 1) . But neither E 2 nor ICI182780 changed the total amounts of ERK1 and ERK2 proteins (data not shown).
Changes in the phosphorylation of kinases
Whether E 2 -induced up-regulation of resistin mRNA expression is related to the kinase pathways was assessed by changes in the phosphorylation of ERK MEK1, p38 MAPK, and Akt (Table 2) . Adipocytes were pretreated with either the ERK MEK1 inhibitor PD98059, the p38 MAPK inhibitor SB203580, or the PI3K inhibitor LY294002 and then treated with 1 nm E 2 for 1 h. Activities of ERK MEK1 were assessed by changes in the amounts of the phosphorylated forms of ERK1 and ERK2. E 2 alone had no effect on ERK1 and ERK2 proteins (data not shown) but increased the amounts of phospho-ERK1, phospho-ERK2, phospho-p38, and phospho-Akt proteins (Table 2) .
In contrast, PD98059 alone reduced the basal activity of ERK MEK1 and in the presence of E 2 , suppressed E 2 -increased levels of phospho-ERK proteins (Table 2) . When compared with the E 2 -treated group, PD98059 prevented E 2 -stimulated expression of resistin mRNA. Regardless of the presence of E 2 , SB203580 pretreatment significantly decreased the amount of phospho-p38 protein in adipocytes relative to the control. SB203580 did not alter increases in resistin gene expression induced by E 2 . LY294002 significantly reduced the amount of phospho-Akt protein in adipocytes treated with or without E 2 when compared with the control. Similar to SB203580, LY294002 neither changed resistin gene expression alone nor significantly affected E 2 -induced increases in resistin mRNA levels.
Whether E 2 -induced alterations in resistin protein production and secretion are dependent on these MAPK or PI3K pathways was also examined (Table 2 ). There was a trend for SB203580 to decrease the basal content of intracellular resistin protein and to increase the basal release of resistin protein after 1 h of treatment. In addition, this p38 MAPK inhibitor decreased E 2 -retained levels of the intracellular resistin protein and slightly further increased E 2 -induced increases in resistin protein release. The effects of PD98059 and LY294002 differed from those of SB203580. There was a trend of PD98059 and LY294002 to increase the basal content of the intracellular resistin protein and to decrease the basal release of the resistin protein after 1 h of treatment. Moreover, PD98059, but not LY294002, significantly affected E 2 -induced alterations in both the intracellular and extracellular resistin protein contents. These data indicated that PD98059 was more significant than SB203580 or LY294002 in modifying E 2 -induced changes in resistin protein contents between the intracellular and extracellular compartments.
Effect of E 2 on resistin mRNA expression depends on the association of ER␣ and C/EBP␣
It has been reported that adipocyte specificity of resistin mRNA expression is a result of the C/EBP␣ binding, thereby leading to the recruitment of transcriptional factors and coactivators (24) . Accordingly, the possibility that E 2 -induced Data are expressed as the mean Ϯ SEM from replicates of three experiments. Serum-starved 3T3-L1 adipocytes were pretreated with or without either cycloheximide (experiment 1; 5 g/ml; 60 min) or ICI182780 (experiment 2; 1 M; 90 min) and then stimulated with 1 nM E 2 for 1 h. Resistin mRNA expression was analyzed by the digoxigenin-PCR ELISA, and its levels are expressed as a percentage of the control after normalization to actin mRNA. The amounts of phospho-ERK1/2 (pERK1/2) proteins were determined by Western blot analysis after 30 min of E 2 treatment and are expressed as a percentage of the control after normalization to actin protein. For each experiment, significant differences between the two groups were assessed after one-way ANOVA and Student-Newman-Keuls multiple range test. ND expression of the resistin gene is mediated through the association of ER with C/EBP␣ and through association of C/EBP␣ with the resistin promoter was also examined (Fig.  3) . First, we examined whether E 2 affected the amounts of C/EBP␣ and ER␣ proteins (Fig. 3, A and B) . Using Western blot analysis, we found that E 2 increased the amount of C/EPB␣ protein in a time-dependent manner (Fig. 3A) . At 1 h, but not at 24 h, of treatment, E 2 did not significantly alter the amounts of total ER␣ and C/EBP␣ proteins (Fig. 3B) . Next, we studied whether E 2 affected the association of ER␣ with C/EBP␣ (Fig. 3, C and D) . Adipocytes were pretreated with either ICI182780 or PD98059 for 90 min and then treated with or without 1 nm E 2 for 1 h. An increase in the association of nuclear ER␣ to C/EBP␣ induced by E 2 was observed when nuclear protein lysates were subjected to the immunoprecipitation of ER␣ (Fig. 3C ) or C/EBP␣ (Fig. 3D) with their respective antisera, and amounts of the two proteins were then determined by Western blot analysis. Treatment with either ICI182780 or PD98059 prevented the E 2 -induced increases in the association of nuclear ER␣ to C/EBP␣ (Fig. 3 , C and D) but did not affect total amounts of either protein (Fig. 3B) . Finally, we further demonstrated whether E 2 affected the association of ER␣ and C/EBP␣ with the resistin gene promoter through the use of the ChIP assay (24) . In this assay, chromatin was isolated and subjected to cross-linking and shearing of the DNA before immunoprecipitation with specific antibodies against ER␣ (Fig. 3E, solid circles) or C/EBP␣ (Fig. 3E, open circles) proteins. The association of ER␣ and C/EBP␣ proteins with the resistin gene promoter was examined by PCR using primers specific for the resistin promoter (as described in Materials and Methods) after the reversal of cross-linking. Using this analysis, we found that 1 nm E 2 for 1 and 6 h, but not for 24 h, induced increases in the association of ER␣ and C/EBP␣ with the resistin promoter (Fig. 3E ), but after 90-min pretreatment with either ICI182780 or PD98059, prevented the E 2 -induced increases in the association of ER␣ and C/EBP␣ with the resistin promoter (Fig. 3F) .
Differences among several estrogens in the regulation of resistin gene expression
Differences in regulating resistin mRNA expression among E 2 , estriol, estrone, genistein, and diethylstilbestrol were also assessed (Fig. 4) . E 2 and genistein, but not estriol, estrone, or diethylstilbestrol, increased the resistin mRNA levels. At a given 1 nm concentration for 6 h treatment, E 2 was more effective than genistein in stimulating resistin mRNA expression.
Discussion
The present study demonstrates that E 2 stimulates resistin gene expression in 3T3-L1 adipocytes. It is likely that E 2 up-regulates resistin mRNA levels by stimulating resistin gene transcription. This conclusion is supported by the findings that treatment of Acti-D prevented the E 2 -induced increases in resistin mRNA levels (Fig. 1, B and C) , that E 2 treatment enhanced the association of C/EBP␣, a transcriptional activator of resistin (24 -26) , with the resistin gene promoter (Fig. 3) , and that overexpression of dominant-negative C/EBP␣ prevented E 2 -induced resistin mRNA expression (unpublished observations). The Acti-D-dependent effect of E 2 suggests that new mRNA synthesis is required for the effect of E 2 . However, E 2 did not affect resistin mRNA stability because it did not alter the basal half-life of resistin mRNA induced by Acti-D alone (Fig. 1C) . Moreover, pretreatment of 3T3-L1 adipocytes with cycloheximide rapidly prevented E 2 -induced increases in resistin mRNA expression ( Table 1 ), suggesting that new protein synthesis is also required for the effect of E 2 .
We attempted to search the signaling proteins required for E 2 induction of resistin gene expression. It is evident from these data that ER␣ inactivation via the antiestrogen ICI182780 (31) prevented the E 2 -induced increases in resistin mRNA levels and ER␣ activity. This demonstrates that functional ER␣ is necessary for the effect of E 2 . We also attempted to find the downstream signaling transducers of ER␣ involved with the activation of resistin mRNA expression. We Data are expressed as the mean Ϯ SEM from replicates of three experiments. Serum-starved 3T3-L1 adipocytes were pretreated with or without either PD98059 (50 M), SB203580 (10 M), or LY294002 (50 M) for 90 min and then stimulated with 1 nM E 2 for 1 h. Resistin mRNA and protein levels are expressed as a percentage of the control after normalization to actin mRNA and protein, respectively. Intra-protein and extra-protein, respectively, represent the intracellular and extracellular levels of resistin protein. The amounts of phospho-ERK1/2 (pERK1/2), phospho-p38 (pp38), and phospho-Akt (pAkt) proteins were determined by Western blot analysis after 30 min of E 2 treatment and are expressed as a percentage of the control after normalization to actin protein. For each kinase inhibitor, significant differences were assessed between the two groups after one-way ANOVA and Student-Newman-Keuls multiple range test. ND, Not determined.
a P Ͻ 0.05, E 2 vs. control or inhibitor vs. control.
observed herein that the specific inhibitors of ERK MEK1, but not p38 MAPK or PI3K, such as PD98059 (28), SB203580 (29) , and LY294002 (30), significantly prevented the E 2 -increased levels of resistin mRNA, and they also respectively antagonized E 2 -induced increases in the amounts of phospho-ERKs, phospho-p38, and phospho-Akt proteins. These observations suggest that the stimulatory effect of E 2 on resistin mRNA expression of 3T3-L1 adipocytes is mediated via a pathway that requires activation of ERK MAPK, but not p38 MAPK and PI3K, activity. The ERK-dependent effect of E 2 was also supported by our observations that ICI182780 reduced E 2 -stimulated MEK1 activity and resistin expression and that PD98059 completely blocked the E 2 -induced increases in the binding of ER to C/EBP␣ and the association of ER␣ and C/EBP␣ with the resistin gene promoter. It was evident that E 2 induced a rapid nuclear translocation of ERK MAPK together with a fast ERK MAPK-dependent activation of some transcriptional factors [i.e. cAMP response element binding protein (CREB), activator protein-1, and ER␣] in rat adipocytes leading to a transcriptional activation of E 2 -responsive genes (i.e. c-fos) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) . Whether this mechanism explains the ERK-dependent effect of E 2 on resistin gene expression was not demonstrated in this study.
The promoter activity and expression of the resistin gene are regulated by a variety of nuclear receptors and of coactivator systems (1, 24 -26, 35) . Because peroxisome proliferator-activated receptor-␥ (PPAR␥) agonist are major negative regulators of resistin (1, 25) and because PPAR␥ mRNA expression is decreased in response to estrogens during adipogenesis of bone marrow stromal cells (36), we measured the amounts of PPAR␥ protein in 3T3-L1 adipocytes after they were treated with 1 nm E 2 for 3, 6, or 24 h. E 2 slightly decreased levels of PPAR␥ protein by 10 -16% during 24 h of treatment (unpublished observations). Whether PPAR␥ mRNA expression and its ER␣-, C/EBP␣-, and DNA-binding activities are altered by E 2 was not determined in this study.
FIG.
3. E 2 (1 nM) increased levels of the C/EBP␣ protein, the association of ER␣ with C/EBP␣, and the association of both proteins with the resistin promoter in 3T3-L1 adipocytes. A, Time-dependent effect of E 2 on C/EBP␣ protein expression was observed; B. E 2 , ICI182780 (1 M), or PD98059 (50 M) did not affect ER␣ and C/EBP␣ protein expression when total lysates were measured by Western blot analysis 1 h after treatment; C and D, ICI182780 and PD98059, respectively, prevented the E 2 -induced increase in the association of ER␣ with C/EBP␣. Nuclear protein lysates were subjected to immunoprecipitation of ER␣ or C/EBP␣ with either ER␣ (C) or C/EBP␣ (D) antisera (black bars), or with NRS (the value is too small to be illustrated) and then determined by Western blot analysis. Levels of C/EBP␣ (C) and ER␣ (D) proteins are expressed as a percentage of the control after normalization to ER␣ and C/EBP␣, respectively. E, E 2 time-dependently stimulated the association of ER␣ and C/EBP␣ with the resistin promoter as determined by the ChIP assay; F, 90 min of pretreatment with either ICI182780 or PD98059 prevented the E 2 -induced increases in the association of ER␣ and C/EBP␣ with the resistin gene promoter. Fragmented DNA not subjected to immunoprecipitation served as the input control, and it did not change among groups (data not shown). Data are expressed as the means Ϯ SE from replicates of three experiments. In A and E, control experiments were set at time 0 when E 2 was added in the beginning, whereas in B, C, D, and F, controls were those that were not treated with E 2 . a and b, Groups with different letters are significantly different (P Ͻ 0.05) from each other for C/EBP␣ or ER␣; *, P Ͻ 0.05 vs. control; #, P Ͻ 0.05, E 2 vs. E 2 ϩ inhibitor (brackets).
We did find herein that E 2 significantly increased levels of the C/EBP␣ protein after 24 h, but not 3 or 6 h, of treatment (Fig.  3A) . At 1-6 h of treatment, E 2 also enhanced the association of nuclear ER␣ with C/EBP␣ and the association of both proteins with the resistin gene promoter (Fig. 3) , whereas ICI182780 antagonized these stimulatory effects of E 2 . Moreover, overexpression of dominant-negative C/EBP␣, but not dominant-negative C/EBP␤, reduced the basal levels of resistin mRNA and prevented E 2 -induced resistin mRNA expression (unpublished observations). These observations imply that the stimulatory effect of E 2 on resistin gene expression of 3T3-L1 adipocytes may be mediated via a pathway in which ER associates with C/EBP␣. This implication is also indirectly supported by the findings that a functional C/EBP␣-binding site was found in the proximal resistin promoter of both murine and human adipocytes to be necessary for the stimulation of transcription from resistin promoter (24 -26) and that endogenous C/EBP␣ was bound to the resistin promoter in adipocytes in association with p300 and CREB-binding protein (24) , which are viewed as coactivators involved in ER activation (23) .
Expression and secretion of resistin protein are differently regulated by certain hormones, such as insulin, IGF-I, GH, dexamethasone, endothelin-1, and vitamin A (1, 4, 27, 35, 37) . We report herein that increased intracellular resistin protein content was observed after 24 h, but not 1-12 h, of E 2 treatment, whereas increased resistin protein release was observed during the entire 24 h of treatment. These observations suggest that E 2 transiently modifies the distribution of resistin protein between the intracellular and extracellular compartments of 3T3-L1 adipocytes. This is consistent with the observation that E 2 can regulate the translocation of the ER␣ (38) . Our previous study implied the involvement of p38 MAPK-dependent pathways in the basal and IGF-I-stimulated distribution of the resistin protein between the intracellular and extracellular compartments (27) . In the present report, we found that PD98059 inhibited E 2 -stimulated ERK MEK1 activity and resistin protein release. Neither SB203580 nor LY294002 significantly prevented E 2 -stimulated resistin protein release by 3T3-L1 adipocytes. These data suggest that the way E 2 signaling increases resistin protein release from 3T3-L1 cells is similar to that by which it increases resistin mRNA levels; it is likely mediated through an ERK-dependent pathway.
Cellular actions of estrogens can be genomic or nongenomic (23). The genomic mechanism through which estrogens affect transcription of estrogen-sensitive genes is by direct binding of activated ER to the estrogen response elements. By contrast, the nongenomic mechanism is that putative membrane ER␣ and ER␤ can modulate the expression of genes without directly binding to DNA but by rapidly activating the MAPK cascade. Our experiments showing that the ER␣ antagonist ICI182780 (31) blocked MEK1 and resistin activation by E 2 suggest the possible involvement of a functional membrane ER␣ in regulating resistin gene expression in 3T3-L1 adipocytes. This conclusion is consistent with those observed for the nongenomic effect of E 2 on the expression of adipocyte uncoupling protein-2 and c-fos genes stimulated by E 2 's activation of the MAPK cascade (22) . It is interesting in our findings that estrogens (i.e. E 2 , estriol, and estrone) and the selective ER modulators (SERMs, such as genistein and diethylstilbestrol) were not entirely consistent in stimulating resistin expression by 3T3-L1 adipocytes 6 h after 1 nm treatment. Possible explanations for this discrepancy are that the distinct types of estrogens and SERMs bind to ER␣ or -␤ in 3T3-L1 adipocytes at varying levels and that coactivators (i.e. CREB-binding protein and p300) and corepressors (i.e. silencing mediator of retinoid and thyroid receptors) of ERs required for the actions of E 2 and SERMs vary with estrogen species or ER forms (23, 34) . However, our study could not exclude the possibility that the genomic mechanism of actions of estrogens and SERMs (23) may help explain their differential effects on resistin expression.
In support of this study, E 2 at 10 nm for 6 h was found to induce a 163% increase in resistin mRNA levels from primary adipocytes isolated from the abdominal adipose tissues of female C57BL/6J mice according to the collagenase-digested method (Ref. 39 and Table 3 ). In addition, pretreatment of these primary cells with 1 m ICI182780 for 90 min prevented E 2 -activated resistin mRNA expression. Moreover, E 2 stimulated a 60% increase in the release of resistin protein from primary adipocytes, and the E 2 activation of resistin release was blocked by ICI182780 pretreatment. In different experiments using C3H10T1/2 mouse adipocytes, which were obtained according to a previously published method (40), ICI182780 pretreatment prevented the E 2 -stimulated increases in resistin mRNA levels, and E 2 significantly increased resistin protein expression and release by C3H10T1/2 cells after 24 h of treatment (Table 3) . These effects are similar to those observed for 3T3-L1 adipocytes. We should note that the doses (1-10 nm) of E 2 used in our study are close to the higher physiological circulating E 2 levels (22, 41) . Similarly, the levels of resistin released from the E 2 -stimulated primary and secondary adipocytes ranged from 32-500 ng/ml, which correspond to higher circulating resistin levels (19 -21) and are compatible with the effective doses (30 -20,000 ng/ml) of resistin in regulating insulin resistance, adipogenesis, and inflammation in cells or ani- mals (13) (14) (15) (16) (17) . Recent studies have shown that estrogen replacement can decrease the adipose mass and insulin resistance in aromatase-knockout mice and postmenopausal women (34) , that E 2 affects inflammation via altering the cytokine levels (42) , and that the effect of estrogens on insulin sensitivity is influenced by the route and dose of administration (41) . For example, at physiological levels, E 2 has a role in maintaining normal insulin sensitivity, but at higher levels (ϳ100 nm), it impairs insulin sensitivity by altering insulin signaling in adipose tissues (41) . Firm conclusions as to whether any of these in vivo effects of E 2 (34, 41, 42) can be explained by its in vitro effects on adipocyte resistin levels will require more thorough studies.
We conclude that E 2 activation of resistin gene expression in 3T3-L1 adipocytes is dependent on mRNA and protein synthesis and is likely mediated through increased mRNA transcription. Although these actions were shown to be mediated via the ER␣, C/EBP␣, and ERK MEK1 pathways, signaling was demonstrated to be likely independent of the p38 MAPK and PI3K pathways. However, inhibitors of ERK MEK1, but not p38 MAPK, modified the E 2 -stimulated distribution of the resistin protein between the intracellular and extracellular compartments of 3T3-L1 adipocytes. Results of this study showing the stimulatory effect of E 2 on resistin production from murine primary and secondary adipocytes appear to support the findings that resistin mRNA and protein levels are higher in female mice than in male mice. Because E 2 , androgen (18 -20) , and progesterone (43) were found to regulate resistin gene expression or protein secretion, it would be of interest to determine whether these sex steroids interact to control resistin levels in different genders in another study. 
ND ND
Data are expressed as the mean Ϯ SEM from triplicate experiments. Serum-starved primary adipocytes (isolated from female C57BL/6J mouse) and C3H10T1/2 adipocytes with respective densities of 5 ϫ 10 5 and 2 ϫ 10 6 cells in a 10-cm plate were pretreated with or without ICI182780 (1 M) for 90 min and then stimulated with E 2 (0 -10 nM) for 6 or 24 h. Resistin mRNA and protein levels are expressed as a percentage of the control after normalization to actin mRNA and protein, respectively. The average levels of resistin released from control primary adipocytes (at 6 h) and control secondary adipocytes (at 6 and 24 h) were 22 Ϯ 2, 24 Ϯ 2, and 106 Ϯ 5 ng/ml, respectively. For each experiment, significant differences were assessed between the two groups after one-way ANOVA and Student-Newman-Keuls multiple range test. ND, Not determined.
a P Ͻ 0.05, E 2 vs. control. b P Ͻ 0.05, E 2 vs. E 2 ϩ ICI182780.
